CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicityTim Sauer, Cliona M. Rooney|Blood|2021Cited by 211
Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1Maike Janssen, Sascha Dietrich, Katharina Weidenauer et al.|Blood|2022Cited by 100
Prediction of complete remission and survival in acute myeloid leukemia using supervised machine learningJan‐Niklas Eckardt, Jan Moritz Middeke, Christoph Röllig et al.|Haematologica|2022Cited by 47
Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European LeukemiaNet risk classificationJan‐Niklas Eckardt, Christoph Röllig, Marius Bill et al.|Leukemia|2023Cited by 36
Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcomeJan‐Niklas Eckardt, Christian Thiede, Sebastian Stasik et al.|Blood Cancer Journal|2023Cited by 34